<!--QuoteEBegin] Drugs Aging. 2006;23(3):227-40. Links A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.Kirby J, Green C, Loveman E, Clegg A, Picot J, Takeda A, Payne E. Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Boldrewood, Southampton, UK.
Alzheimer's disease (AD) is the most common form of dementia and is characterised by a worsening of cognition, functional ability, and behaviour and mood. The objective of this study was to review the clinical and cost-effectiveness of memantine for the treatment of patients with moderately severe to severe AD. To achieve this, a systematic search and review of the clinical and cost effectiveness literature for memantine was undertaken. The literature search covered the period from the inception of MEDLINE, Cochrane Library, EMBASE and other electronic databases until July 2004. The search included randomised controlled trials (RCTs) and full economic evaluations that assessed the use of memantine in patients with moderately severe to severe AD.Two published RCTs were included in this review; in one of these trials the participants were already being treated with donepezil. The two RCTs showed benefit for patients receiving memantine compared with placebo on the outcome measures of the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia, the Clinician's Interview-Based Impression of Change Plus Caregiver Input, and the Severe Impairment Battery, and that memantine appeared to be slightly more effective in patients already receiving a stable dose of donepezil. Five cost-effectiveness studies were included in the review. Although these studies reported cost reductions and improved outcomes with memantine, the evaluations were based on a number of assumptions.In conclusion, memantine appears to be beneficial when assessed using functional and global measurements. However, the effect of memantine on cognitive scores and behaviour and mood outcomes is less clear. Cost-effectiveness is dependent upon assumptions surrounding clinical effect and context-specific cost data.
PMID: 16608378 [PubMed - in process]
Cholinesterase inhibitors for Alzheimer's disease.Birks J. University of Oxford, Department of Clinical Geratology, Radcliffe Infirmary, Woodstock Road, Oxford, UK, OX2 6HE. jacqueline.birks@geratol.ox.ac.uk
BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). Despite the evidence from the clinical studies and the intervening clinical experience the debate on whether ChEIs are effective continues. OBJECTIVES: To assess the effects of donepezil, galantamine and rivastigmine in people with mild, moderate or severe dementia due to Alzheimer's disease. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched using the terms 'donepezil', 'E2020' , 'Aricept' , galanthamin* galantamin* reminyl, rivastigmine, exelon, "ENA 713" and ENA-713 on 12 June 2005. This Register contains up-to-date records of all major health care databases and many ongoing trial databases. SELECTION CRITERIA: All unconfounded, blinded, randomized trials in which treatment with a ChEI was compared with placebo or another ChEI for patients with mild, moderate or severe dementia due to Alzheimer's disease. DATA COLLECTION AND ANALYSIS: Data were extracted by one reviewer (JSB), pooled where appropriate and possible, and the pooled treatment effects, or the risks and benefits of treatment estimated. MAIN RESULTS: The results of 13 randomized, double blind, placebo controlled trials demonstrate that treatment for periods of 6 months and one year, with donepezil, galantamine or rivastigmine at the recommended dose for people with mild, moderate or severe dementia due to Alzheimer's disease produced improvements in cognitive function, on average -2.7 points (95%CI -3.0 to -2.3), in the midrange of the 70 point ADAS-Cog Scale. Study clinicians blind to other measures rated global clinical state more positively in treated patients. Benefits of treatment were also seen on measures of activities of daily living and behaviour. None of these treatment effects are large.There is nothing to suggest the effects are less for patients with severe dementia or mild dementia, although there is very little evidence for other than mild to moderate dementia.More patients leave ChEI treatment groups, approximately 29 %, on account of adverse events than leave the placebo groups (18%).There is evidence of more adverse events in total in the patients treated with a ChEI than with placebo. Although many types of adverse event were reported, nausea, vomiting, diarrhoea, were significantly more frequent in the ChEI groups than in placebo.There are four studies, all supported by one of the pharmaceutical companies, in which two ChEIs were compared, two studies of donepezil compared with galantamine, and two of donepezil compared with rivastigmine. In three studies the patients were not blinded to treatment, only the fourth, DON vs RIV/Bullock is double blind. Two of the studies provide little evidence, they are of 12 weeks duration, which is barely long enough to complete the drug titration. There is no evidence from DON vs GAL/Wilcock of a treatment difference between donepezil and galantamine at 52 weeks for cognition, activities of daily living, the numbers who leave the trial before the end of treatment, the number who suffer any adverse event, or any specific adverse event.There is no evidence from DON vs RIV/Bullock of a difference between donepezil and rivastigmine for cognitive function, activities of daily living and behavioural disturbance at two years. Fewer patients suffer adverse events on donepezil than rivastigmine. AUTHORS' CONCLUSIONS: The three cholinesterase inhibitors are efficacious for mild to moderate Alzheimer's disease. It is not possible to identify those who will respond to treatment prior to treatment. There is no evidence that treatment with a ChEI is not cost effective. Despite the slight variations in the mode of action of the three cholinesterase inhibitors there is no evidence of any differences between them with respect to efficacy. There appears to be less adverse effects associated with donepezil compared with rivastigmine. It may be that galantamine and rivastigmine match donepezil in tolerability if a careful and gradual titration routine over more than three months is used. Titration with donepezil is more straightforward and the lower dose may be worth consideration.
PMID: 16437532 [PubMed - indexed for MEDLINE]
See you around.
Edited by nootropikamil, 21 July 2006 - 11:42 PM.
#23
scottl
-
-
Guest
-
2,177 posts
-
2 ₮
Posted 21 July 2006 - 10:29 PM
Adam, 1. It is unfortunately true that there are....far too many people on these boards looking for a fast biochemical fix where there is none. For any part I have played in that e.g. I posted that thread on avant that started the....Breverman stuff me aculpa. I have written an article on the opposite way of dealing with things which is applicable to more (here FYI: http://www.mindandmu...eID=38&artID=30and tried to remind people of this. Having said that 2. There are people who have benefited from nootropics....It apparently made a huge difference...you can search the board...forget who it was....though they have not done much for me aside from neurostim and biotests...whatever it was called. But people have benfited. I believe Lynx was one. Soo while they ain't a panacea, I do believe they can be of benefit. I've a supply of tianeptine I've had for ages. There was no point in trying it till I had everything else in order i.e. while I was still being stressed. I've adressed everying else and will probably try it in the next few months. Anyway I beleive they are not the panacea you made them out to be a year ago, nor as useless as many would believe. But you gotta have your metaphorical house in order first, and they are very individual and may or may not do anything for ya.
#24
doug123
- Topic Starter
-
-
Guest
-
2,424 posts
-
-1 ₮
Posted 21 July 2006 - 10:34 PM
I think that many people are interested in this stuff as a hobby (literally taking pills!) These days, there are so many pills to choose from, I think it's a good idea to be as choosy as possible; especially since most of us don't have a limitless budget.
I think nootropics have helped me too...but that could be because I wanted to convince myself they work. I got to a point with the pills I was taking such that they started to hurt my performance in school due to the psychosis. I thought every professor and TA had some kind of conspriacy against me...I ended up dropping out. I am trying to convince myself to go back to school...it's hard going back.
#25
eternaltraveler
-
-
Guest, Guardian
-
6,471 posts
-
155 ₮
-
Location:Silicon Valley, CA
Posted 21 July 2006 - 10:57 PM
i never found any significant benefit from any nootropics. Drugs like aricep may be a different matter, but my brain works just fine now, so why risk screwing it up.
#26
eternaltraveler
-
-
Guest, Guardian
-
6,471 posts
-
155 ₮
-
Location:Silicon Valley, CA
Posted 21 July 2006 - 10:59 PM
The side effects from tianeptine are QUITE terrible and occur in WAY too many patients for MDs to prescribe without getting a million calls...geez....20% of patients experience dry mouth, 15% constipation, dizziness 13%, drowsiness 10%, postural hypo tension 3%, Insomnia and nightmares 20%! It's no wonder this drug never caught on!
compared to other drugs that treat depression/anxiety the side effects of tianeptine may be superior, and so if you really have one of the conditions its indicated for it may be of use. Of course this doesn't address your original point of whether or not it induces neurogenisis in healthy subjects.
#27
scottl
-
-
Guest
-
2,177 posts
-
2 ₮
Posted 21 July 2006 - 11:54 PM
Those side effects are...in no way out of the ordinary of many drugs that are being prescribed (you really have no idea), and keep in mind for myself and I think many/most of the people on the board we are only talking about a cycle or two or the stuff, not long term treatment.
#28
ikaros
-
-
Guest
-
334 posts
-
5 ₮
Posted 22 July 2006 - 08:56 AM
I was prescribed tianeptine for OCD and so far I can report that it has had a beneficial effect on my mood and reduced anxiety levels to a very low level. What's more is that it seems that my ability to cope with stressful events is greatly improved and having OCD, you'll have a lot of them. A problem with OCD is that you can't shut your mind down, all you can do is think if you want to feel normal and think about complex problems all the time. It's like being stuck on somekind of fixed path. I do not know if this is a proof of neuroplasticity(which shoold be the brain's ability to adapt to new experiences and in a more abstract sense, keep the inside in objective harmony with the outside), but I can note that my overall ability to be objective (without falling into a pit of obsessing) to life's events has improved.
#29
doug123
- Topic Starter
-
-
Guest
-
2,424 posts
-
-1 ₮
Posted 13 August 2006 - 05:51 AM
I was prescribed tianeptine for OCD and so far I can report that it has had a beneficial effect on my mood and reduced anxiety levels to a very low level. What's more is that it seems that my ability to cope with stressful events is greatly improved and having OCD, you'll have a lot of them. A problem with OCD is that you can't shut your mind down, all you can do is think if you want to feel normal and think about complex problems all the time. It's like being stuck on somekind of fixed path. I do not know if this is a proof of neuroplasticity(which shoold be the brain's ability to adapt to new experiences and in a more abstract sense, keep the inside in objective harmony with the outside), but I can note that my overall ability to be objective (without falling into a pit of obsessing) to life's events has improved.
If it works for you, that is great. Did you experience any of the negative side effects and had you tried anything else before? I am curious if maybe some of this data may be exaggerated.., What country are you in? This drug seems to have a particularly unfavorable side effect profile and it seems there are now better options available in medicine -- I think I understand why this drug never made it into the US pharmacopeia. over 1/3-1/5 of your patients experience dry mouth, 1/4-1/5 experience constipation, 1/5 experience dizziness/syncope, 1/6 experience drowsiness, 1/11 experience postural hypotension, and 1/5 experience Insomnia and nightmares -- uh, doc, is there something else I can try? I guess it could be prescribed if better studied and tolerated agents fail to work. Side effects Tianeptine was both studied for short-term (3 month) and long-term treatment (12 months) and equally well tolerated. The studies encompassed 1,300 to nearly 3,000 patients each.
Side effects are as follows (Amitriptyline vs Tianeptine):
dry mouth (38 vs 20%) constipation (19 vs 15%) dizziness/syncope (23 vs 13%) drowsiness (17 vs 10%) postural hypotension (8 vs 3%) Insomnia and nightmares occur more often in tianeptine than in amitriptyline recipients (7 vs 20%)
sponsored ad
-
-
Advert
#30
ikaros
-
-
Guest
-
334 posts
-
5 ₮
Posted 13 August 2006 - 08:45 AM
Nootropikamil, compared to the SSRIs tianeptine is an innocent child. I did experience one side-effect which is usually common to serotonergic antidepressants and it was slight muscle cramps, but those weren't anything serious and went away in 5 days. By the way because I was diagnosed OCD, I have tried all SSRIs out there and I can say most of them are packed with side-effects and not just with side-effects you listed for tianeptine, but much worse kind of side-effects, (on fluvoxamine) for me the worst was a hypomanic episode which lasted 2 months (my doc rushed to diagnose me as a bipolar, but it was actually the med). I've been on tianeptine for over a month now and I still can't find anything bad about it, maybe slight energy rush time to time, but who whines about that, helps me pull more work and at the university I manage to get more studying done also.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
Reply to quoted posts Clear
- LONGECITY
- → Science & Health
- → Brain Health
- site rules
Ad Notice
You Are Using Ad Block Plus or some other advert blocking software. More info here: "https://www.longecity.org/forum/topic/84454-please-disable-adblockers/
This window will close in 5 second(s)
|